Statin use in europe
Pro Research Analysisby 
Searched over 200M research papers
Statin Use Trends and Patterns in Europe
Statin use has increased significantly across Europe over the past decades. Between 1997 and 2003, all studied European countries saw a rise in statin prescriptions, with the highest increases observed in Ireland and Norway, and the lowest in Italy. This growth was mainly due to more patients being treated and, to a lesser extent, higher prescribed daily doses. Statins became the dominant lipid-lowering therapy, although fibrates remained popular in France, Belgium, and Germany during this period 12. From 2010 to 2018, statin use continued to rise or remain stable in countries like Denmark, Italy, and Spain, while staying constant in the UK .
Statin Prescribing and Guideline Implementation in Europe
Despite the widespread use of statins, there are notable gaps between clinical guidelines and real-world practice. A large cross-sectional study across 18 European countries found that only 54% of patients achieved the 2016 European Society of Cardiology (ESC) cholesterol goals, and just 33% met the stricter 2019 targets. High-intensity statin use was relatively low, especially in very high-risk patients, and the use of combination therapies with ezetimibe or PCSK9 inhibitors was rare. This suggests that even with optimized statin therapy, additional non-statin lipid-lowering treatments may be needed to help more patients reach recommended cholesterol targets .
Statin Use and Cardiovascular Outcomes
Although statin utilization increased dramatically in Western Europe from 2000 to 2012, studies found no direct association between higher statin use at the population level and reductions in coronary heart disease (CHD) mortality. This indicates that other factors, such as public health initiatives, aging populations, and changes in healthcare policy, may also play significant roles in CHD outcomes .
Statin Eligibility and International Guideline Comparisons
The 2021 European ESC guidelines for primary prevention of cardiovascular disease use a new risk model and higher treatment thresholds, resulting in fewer people being eligible for statins compared to US and UK guidelines. For example, only 4% of individuals aged 40–69 years qualified for statins under the 2021 ESC guidelines, compared to 34% under US guidelines and 26% under UK guidelines. Lowering the treatment thresholds in the ESC guidelines would increase eligibility and improve sensitivity for detecting future cardiovascular events 78.
Statin Use and Mental Health in European Populations
Research shows that statin use in European populations is associated with a reduced risk of post-stroke depression and may lower depressive symptoms in White Europeans. However, among ethnic minorities in the UK, statin use was linked to increased depressive symptoms, highlighting the need for further research into ethnic differences in statin effects 69.
Conclusion
Statin use in Europe has grown substantially, with significant variation between countries and persistent gaps between guideline recommendations and clinical practice. While statins are widely prescribed, many high-risk patients do not achieve recommended cholesterol targets, and eligibility for statin therapy varies greatly depending on the guidelines used. Additionally, the impact of statins on mental health may differ across ethnic groups. Continued efforts are needed to optimize statin use, close the gap between guidelines and practice, and ensure equitable cardiovascular care across Europe.
Sources and full results
Most relevant research papers on this topic